Effect of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, on Conjunctival Staining in Patients with Keratoconjunctivitis Sicca: A Pooled Analysis of Phase 2b/3 and 3 Clinical Trials

Robert Smyth-Medina,Josh Johnston,Douglas K. Devries,April L Jasper,Shane R. Kannarr,Barry A. Schechter,Bridgitte Shen Lee,George Varghese,Abayomi Ogundele,Charles Darby,Paul M. Karpecki,Jodi Luchs

Effect of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, on Conjunctival Staining in Patients with Keratoconjunctivitis Sicca: A Pooled Analysis of Phase 2b/3 and 3 Clinical Trials

2019

Robert Smyth-Medina
Josh Johnston
Douglas K. Devries
April L Jasper
Shane R. Kannarr
Barry A. Schechter
Bridgitte Shen Lee
George Varghese
Abayomi Ogundele
Charles Darby
Paul M. Karpecki
Jodi Luchs

Abstract Purpose: Keratoconjunctivitis sicca (KCS), a multifactorial disease, is the most common ocular condition for patients seeking medical treatment and is characterized by ocular burning, stin...

Keywords:

Diabetes mellitus
Clinical trial
Dermatology
Anesthesia
Staining
Medicine
KERATOCONJUNCTIVITIS SICCA
medical treatment
pooled analysis
in patient
multifactorial disease

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations